Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 5.7% - Should You Sell?

Key Points

• Coeptis Therapeutics shares fell by 5.7% during trading, closing at $16.51 after dropping from $17.50.
• The company reported a quarterly loss of ($1.17) earnings per share (EPS) with revenue of only $0.20 million.
• Coeptis Therapeutics is focused on developing cell therapy platforms aimed at treating various types of cancers, including products like CD38-GEAR-NK and SNAP-CAR.

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) dropped 5.7% during trading on Monday . The company traded as low as $15.75 and last traded at $16.51. Approximately 53,899 shares changed hands during trading, a decline of 9% from the average daily volume of 58,983 shares. The stock had previously closed at $17.50.

Coeptis Therapeutics Trading Down 5.7%

The company has a debt-to-equity ratio of 0.02, a current ratio of 0.83 and a quick ratio of 0.83. The business's 50 day moving average is $12.86 and its 200 day moving average is $10.46. The stock has a market cap of $79.58 million, a price-to-earnings ratio of -2.85 and a beta of -0.57.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.17) earnings per share (EPS) for the quarter. The business had revenue of $0.20 million for the quarter.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.